Effects of AFQ056 on Language Learning in Young Children With Fragile X Syndrome (FXS)
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Mavoglurant (Primary)
- Indications Fragile X syndrome
- Focus Therapeutic Use
- 11 Sep 2017 Status changed from not yet recruiting to recruiting.
- 11 Apr 2017 Planned initiation date changed from 1 May 2017 to 5 Jun 2017.
- 03 Oct 2016 New trial record